260
Views
18
CrossRef citations to date
0
Altmetric
Drug Evaluations

Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant

, MD, , MD, , MD, , Pharm D BCOP, , MD & , MD
Pages 1607-1614 | Published online: 24 Nov 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Rudolph M. Navari. (2016) The safety and efficacy of NEPA (netupitant and palonosetron) in the treatment of chemotherapy-induced nausea and vomiting. Expert Review of Quality of Life in Cancer Care 1:4, pages 263-268.
Read now
Rudolph M. Navari. (2016) The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting. Expert Opinion on Drug Safety 15:3, pages 343-356.
Read now

Articles from other publishers (15)

Liya Liu, Youqin Chen, Ying Cheng, Meizhu Wu, Jie Li, Jiapeng Li, Thomas Joseph Sferra, Senthilkumar Sankararaman, Jianfeng Chu, Aling Shen & Jun Peng. (2023) Refined Baohe formula protects against 5-fluorouracil-induced intestinal mucositis by modulating AKT pathway in CT-26 tumor-bearing mice. Pharmacological Research - Modern Chinese Medicine 7, pages 100230.
Crossref
Rudolph M. Navari. 2019. International Manual of Oncology Practice. International Manual of Oncology Practice 1007 1045 .
Akimitsu Maeda, Takashi Ura, Chisa Asano, Ikue Haegawa, Motoo Nomura, Azusa Komori, Yukiya Narita, Hiroya Taniguchi, Shigenori Kadowaki, Kei Muro, Yoshitsugu Horio, Tatsuya Yoshida, Isao Oze, Masaki Kajita & Akiyoshi Mizutani. (2016) A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin. Asia-Pacific Journal of Clinical Oncology 12:3, pages 254-258.
Crossref
Rudolph M. Navari. 2016. Management of Chemotherapy-Induced Nausea and Vomiting. Management of Chemotherapy-Induced Nausea and Vomiting 163 176 .
Rudolph M. Navari. 2016. Management of Chemotherapy-Induced Nausea and Vomiting. Management of Chemotherapy-Induced Nausea and Vomiting 1 3 .
Rudolph M. Navari. 2015. International Manual of Oncology Practice. International Manual of Oncology Practice 779 804 .
Rudolph M. Navari. (2014) Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. European Journal of Pharmacology 722, pages 180-186.
Crossref
Rudolph M. Navari, Cindy K. Nagy & Sarah E. Gray. (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supportive Care in Cancer 21:6, pages 1655-1663.
Crossref
Rudolph M. Navari. (2013) Management of Chemotherapy-Induced Nausea and Vomiting. Drugs 73:3, pages 249-262.
Crossref
Thao T. Vo & Jeanenne J. Nelson. (2012) Cardiovascular Events in Cancer Patients Treated with Highly or Moderately Emetogenic Chemotherapy: Results from a Population-Based Study. Journal of Cancer Epidemiology 2012, pages 1-12.
Crossref
Rudolph M. Navari. (2012) Treatment of chemotherapy-induced nausea. Community Oncology 9:1, pages 20-26.
Crossref
Nagi B. KumarNagi B. Kumar. 2012. Nutritional Management of Cancer Treatment Effects. Nutritional Management of Cancer Treatment Effects 107 130 .
William L. Hasler. 2012. Gastroparesis. Gastroparesis 279 288 .
Rudolph M. Navari, Sarah E. Gray & Andrew C. Kerr. (2011) Olanzapine Versus Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Randomized Phase III Trial. The Journal of Supportive Oncology 9:5, pages 188-195.
Crossref
Bruno Vincenzi, Giuseppe Tonini & Daniele Santini. (2010) Aprepitant for Erlotinib-Induced Pruritus. New England Journal of Medicine 363:4, pages 397-398.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.